147 related articles for article (PubMed ID: 31364336)
1. Ceftobiprole: pharmacokinetics and PK/PD profile.
Azanza Perea JR; Sádaba Díaz de Rada B
Rev Esp Quimioter; 2019 Sep; 32 Suppl 3(Suppl 3):11-16. PubMed ID: 31364336
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and Dosing of Ceftobiprole Medocaril for the Treatment of Hospital- and Community-Acquired Pneumonia in Different Patient Populations.
Torres A; Mouton JW; Pea F
Clin Pharmacokinet; 2016 Dec; 55(12):1507-1520. PubMed ID: 27272266
[TBL] [Abstract][Full Text] [Related]
3. Probability of target attainment for ceftobiprole as derived from a population pharmacokinetic analysis of 150 subjects.
Lodise TP; Pypstra R; Kahn JB; Murthy BP; Kimko HC; Bush K; Noel GJ; Drusano GL
Antimicrob Agents Chemother; 2007 Jul; 51(7):2378-87. PubMed ID: 17387149
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and pharmacodynamics of ceftobiprole, an anti-MRSA cephalosporin with broad-spectrum activity.
Murthy B; Schmitt-Hoffmann A
Clin Pharmacokinet; 2008; 47(1):21-33. PubMed ID: 18076216
[TBL] [Abstract][Full Text] [Related]
5. A series of pharmacokinetic studies of ceftaroline fosamil in select populations: normal subjects, healthy elderly subjects, and subjects with renal impairment or end-stage renal disease requiring hemodialysis.
Riccobene T; Jakate A; Rank D
J Clin Pharmacol; 2014 Jul; 54(7):742-52. PubMed ID: 24431097
[TBL] [Abstract][Full Text] [Related]
6. Identification of optimal renal dosage adjustments for high-dose extended-infusion cefepime dosing regimens in hospitalized patients.
Zasowski E; Bland CM; Tam VH; Lodise TP
J Antimicrob Chemother; 2015 Mar; 70(3):877-81. PubMed ID: 25381169
[TBL] [Abstract][Full Text] [Related]
7. Application of pharmacokinetic/pharmacodynamic modelling and simulation for the prediction of target attainment of ceftobiprole against meticillin-resistant Staphylococcus aureus using minimum inhibitory concentration and time-kill curve based approaches.
Barbour AM; Schmidt S; Zhuang L; Rand K; Derendorf H
Int J Antimicrob Agents; 2014 Jan; 43(1):60-7. PubMed ID: 24183800
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetics of cefepime in febrile neutropenia: implications for dose-dependent susceptibility and contemporary dosing regimens.
Rhodes NJ; Grove ME; Kiel PJ; O'Donnell JN; Whited LK; Rose DT; Jones DR; Scheetz MH
Int J Antimicrob Agents; 2017 Sep; 50(3):482-486. PubMed ID: 28668694
[TBL] [Abstract][Full Text] [Related]
9. Population pharmacokinetics of doripenem in Japanese subjects and Monte-Carlo simulation for patients with renal impairment.
Matsuo Y; Ishibashi T; Kubota R; Wajima T
J Infect Chemother; 2015 Feb; 21(2):123-9. PubMed ID: 25487084
[TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetic analysis of ceftobiprole for treatment of complicated skin and skin structure infections.
Kimko H; Murthy B; Xu X; Nandy P; Strauss R; Noel GJ
Antimicrob Agents Chemother; 2009 Mar; 53(3):1228-30. PubMed ID: 19075059
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic/pharmacodynamic analysis to evaluate ceftaroline fosamil dosing regimens for the treatment of community-acquired bacterial pneumonia and complicated skin and skin-structure infections in patients with normal and impaired renal function.
Canut A; Isla A; Rodríguez-Gascón A
Int J Antimicrob Agents; 2015 Apr; 45(4):399-405. PubMed ID: 25700566
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of ceftaroline in normal body weight and obese (classes I, II, and III) healthy adult subjects.
Justo JA; Mayer SM; Pai MP; Soriano MM; Danziger LH; Novak RM; Rodvold KA
Antimicrob Agents Chemother; 2015 Jul; 59(7):3956-65. PubMed ID: 25896707
[TBL] [Abstract][Full Text] [Related]
13. Antibiotic Dosing in Continuous Renal Replacement Therapy.
Shaw AR; Mueller BA
Adv Chronic Kidney Dis; 2017 Jul; 24(4):219-227. PubMed ID: 28778361
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and Safety of Ceftobiprole in Pediatric Patients.
Rubino CM; Polak M; Schröpf S; Münch HG; Smits A; Cossey V; Tomasik T; Kwinta P; Snariene R; Liubsys A; Gardovska D; Hornik CD; Bosheva M; Ruehle C; Litherland K; Hamed K
Pediatr Infect Dis J; 2021 Nov; 40(11):997-1003. PubMed ID: 34533489
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and Target Attainment of Ceftobiprole in Asian and Non-Asian Subjects.
Muller AE; Punt N; Engelhardt M; Schmitt-Hoffmann AH; Mouton JW
Clin Pharmacol Drug Dev; 2018 Sep; 7(7):781-787. PubMed ID: 29768717
[TBL] [Abstract][Full Text] [Related]
16. Ceftobiprole medocaril in the treatment of hospital-acquired pneumonia.
Scheeren TW
Future Microbiol; 2015; 10(12):1913-28. PubMed ID: 26573022
[TBL] [Abstract][Full Text] [Related]
17. Ceftobiprole: a review of a broad-spectrum and anti-MRSA cephalosporin.
Zhanel GG; Lam A; Schweizer F; Thomson K; Walkty A; Rubinstein E; Gin AS; Hoban DJ; Noreddin AM; Karlowsky JA
Am J Clin Dermatol; 2008; 9(4):245-54. PubMed ID: 18572975
[TBL] [Abstract][Full Text] [Related]
18. Population pharmacokinetics and dosing simulations of cefepime in septic shock patients receiving continuous renal replacement therapy.
Carlier M; Taccone FS; Beumier M; Seyler L; Cotton F; Jacobs F; Roberts JA
Int J Antimicrob Agents; 2015 Oct; 46(4):413-9. PubMed ID: 26208469
[TBL] [Abstract][Full Text] [Related]
19. Ceftobiprole for the treatment of pneumonia.
Cillóniz C; Dominedò C; Garcia-Vidal C; Torres A
Rev Esp Quimioter; 2019 Sep; 32 Suppl 3(Suppl 3):17-23. PubMed ID: 31364337
[TBL] [Abstract][Full Text] [Related]
20. Selection of dosing regimen with WST11 by Monte Carlo simulations, using PK data collected after single IV administration in healthy subjects and population PK modeling.
Fabre MA; Fuseau E; Ficheux H
J Pharm Sci; 2007 Dec; 96(12):3444-56. PubMed ID: 17854075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
